The aging process known as senescence is a mechanism involved in the failure of CAR T-cell therapy, according to a study by researchers at the Mayo Clinic.
Mayo Clinic researchers have developed a promising way to deliver treatment directly to cholangiocarcinoma tumors, a rare and aggressive bile duct cancer with limited treatment options, using milk-derived nanoparticles that act like guided delivery vehicles. The study points to a potential targeted genetic therapy designed to attack cancer cells while sparing healthy tissue.
